In vitro fertilization for patients with poor response and occult ovarian failure: A randomized trial

Reproductive Technologies

Volumn 10, Issue 2, 2000, Pages 98-102

  Ragni, G ^a   De Lauretis Yankowski, L ^a   Piloni, S ^a   Vegetti, W ^a   Guermandi, E ^a   Colombo, M ^a   Crosignani, P G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; TRIPTORELIN; UROFOLLITROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESENSITIZATION; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; FETUS HEART; HEART CONTRACTION; HUMAN; HUMAN CELL; INTRACYTOPLASMIC SPERM INJECTION; MENSTRUAL CYCLE; OOCYTE; OVARY; OVARY INSUFFICIENCY; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; STIMULATION; TREATMENT FAILURE; TREATMENT OUTCOME; ULTRASOUND;

EID: 0033828010     PISSN: 15284840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients
2. A randomized prospective study on the effect of short and long buserelin treatment in women with repeated unsuccessful in vitro fertilization (IVF) cycles due to inadequate ovarian response
3. The poor-responder patient in an in vitro fertilization-embryo transfer program
4. Increased human menopausal gonadotropin dose during the early follicular phase: Effect on follicular recruitment and treatment outcome
5. High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization
6. Doubling the human menopausal gonadotrophin dose in the course of an in vitro fertilization treatment cycle in low responders: A randomized study
7. Aetiological factors involved in the low response to gonadotrophins in infertile women with normal basal serum follicle stimulating hormone levels
8. The value of increasing the dose of human menopausal gonadotropins in women who initially demonstrate a poor response
9. The prognostic importance of the number of oocytes retrieved and estradiol levels in poor and normal responders in in vitro fertilization (IVF) treatment
10. Significance of oestradiol values in IVF-ET under a combined GnRH analogue desentization and simultaneous gonadotrophin stimulation for the outcome of pregnancies
11. Differences in ovarian stimulation in human menopausal gonadotropin treated woman may be related to follicle-stimulating hormone accumulation
12. Ovarian response of individuals to different doses of human menopausal gonadotropin
13. Exogenous follicle stimulating hormone ovarian reserve test (EFORT): A simple and reliable screening test for detecting ″poor responders″ in in vitro fertilization
14. Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: A randomized, double-blind, placebo-control trial
15. Comparison of ″poor″ responders with ″good″ responders using a standard buserelin/human menopausal gonadotrophin regime for in vitro fertilization
16. The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate/human menopausal gonadotropin in women with a poor ovarian response
17. Addition of buserelin to human menopausal gonadotrophins in patients with failed stimulations for IVF or GIFT
18. In vitro fertilization: Influence of women's age on pregnancy rates
19. Effect of age on response to human menopausal gonadotropin stimulation
20. Significance of basal follicle-stimulating hormone levels in women with one ovary in a program of in vitro fertilization
21. The impact of ovarian cystectomy on ovarian response to stimulation during in vitro fertilization cycles
22. The effects of ovarian adhesive disease upon follicular development in cycles of controlled stimulation for in vitro fertilization
23. Performance of patients with a ″frozen pelvis″ in an in vitro fertilization program
24. The effect of periovarian adhesions on follicular development in patients undergoing ovarian stimulation for in vitro fertilization-embryo transfer
25. Investigation of impaired ovarian function as a contributing factor to infertility in women with pelvic adhesions
26. The treatment of infertility associated with endometriosis by in vitro fertilization
27. The effect of endometriomas on in vitro fertilization outcome
28. Anthropometric indicators and response to gonadotrophin for ovulation induction
29. Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by the clomiphene citrate challenge test
30. Effect of smoking on ovarian reserve and ovarian stimulation in in vitro fertilization and embryo transfer
31. Premature luteinization: Could it be an early manifestation of low ovarian reserve?
32. Intensive hormone monitoring in women with unexplained infertility: Evidence for subtle abnormalities suggestive of diminished ovarian reserve
33. Inhibin, follicle-stimulating hormone, and age as predictors of ovarian response in in vitro fertilization cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment
34. Day 3 serum inhibin B is predictive of assisted reproductive technologies outcome
35. Prediction of individual response to controlled ovarian hyperstimulation by means of a clomiphene citrate challenge test
36. Efficacy of selection criteria for ovarian reserve screening using the clomiphene citrate challenge test in a tertiary fertility center population
37. The Lupron screening test: Tailoring the use of leuprolide acetate in ovarian stimulation for in vitro fertilization
38. Occult ovarian failure
39. Ovarian stimulation in previous failures from in vitro fertilization: Distinction of two groups of poor responders
40. Utilization of GnRH agonists for poor responders in an IVF programme
41. The relative success of gonadotropin-releasing hormone analogue, clomiphene citrate, and gonadotropin in 1,099 cycles of in vitro fertilization
42. Treatment of low responders
43. Preferred protocol: Controlled ovarian stimulation
44. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization
45. Mini-dose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels
46. A protocol using a low dose of gonadotropin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3
47. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization
48. A prospective randomized comparison between long and discontinuous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization
49. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders
50. Comparison of ovarian stimulation regimens for in vitro fertilization (IVF) with and without a gonadotropin-releasing hormone (GnRH) agonist: Results of a randomized study
51. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders
52. Suppression and flare regimens of gonadotropin-releasing hormone agonist. Use in women with different basal gonadotropin values in an in vitro fertilization program
53. Short protocol of gonadotropin releasing hormone agonist administration gave better results in long protocol poor responders in IVF-ET
54. Clomiphene citrate and hMG: An alternative stimulation protocol for selected failed in vitro fertilization patients
55. In vitro fertilization with low-dose clomiphene citrate stimulation in women who respond poorly to superovulation
56. Adjuvant growth hormone treatment during in vitro fertilization: A randomized, placebo-controlled study
57. A double-blind cross-over controlled study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous poor responders to in vitro fertilization
58. Adjuvant growth hormone therapy in poor responders to in vitro fertilization: A prospective randomized placebo-controlled double-blind study
59. Double-blind placebo controlled study: Human biosynthetic growth hormone for assisted reproductive technology
60. The place of cotreatment with growth hormone and human menopausal gonadotropin (hMG) in ovarian stimulation
61. The day of initiation of human menopausal gonadotropin stimulation affects follicular growth in in vitro fertilization cycles
62. Increasing the human menopausal gonadotropin dose-does the response really improve?
63. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome
64. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: A prospective, multicenter, randomized, clinical trial
65. Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle
66. Natural cycles for in vitro fertilization: Cost-effectiveness analysis and factors influencing outcome